Research programme: antibody drug conjugates - MacroGenics

Drug Profile

Research programme: antibody drug conjugates - MacroGenics

Alternative Names: MGC-018

Latest Information Update: 20 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Synthon
  • Class Bispecific antibodies; Drug conjugates; Recombinant proteins
  • Mechanism of Action CD276 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Solid tumours

Most Recent Events

  • 01 Apr 2017 Pharmacodynamics and Pharmacokinetics data from in vitro and preclinical studies presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 21 Dec 2016 MacroGenics announces intention to submit an IND in 2018 (MacroGenics Form 8-K, filed in December 2016).
  • 12 Dec 2016 MacroGenics in-licenses linker-drug technology from Synthon Biopharmaceuticals for MGC 018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top